CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRVO CervoMed

Trading 04-14 09:40:56 EDT

4.15

+0.14

+3.37%

High4.15	Low4.09	Vol1.77K
Open4.09	D1 Closing4.01	Amplitude1.37%
Mkt Cap38.35M	Tradable Cap20.45M	Total Shares9.25M
T/O7.28K	T/O Rate0.04%	Tradable Shares4.93M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":4.145,"timestamp":1776173990222,"preClose":4.01,"halted":0,"volume":1774,"delay":0,"changeRate":0.03366583541147127,"floatShares":4934300,"shares":9252719,"eps":-2.982424,"marketStatus":"Trading","change":0.135,"latestTime":"04-14 09:40:56 EDT","open":4.09,"high":4.145,"low":4.09,"amount":7278.653701,"amplitude":0.013716,"askPrice":4.25,"askSize":62,"bidPrice":4.09,"bidSize":345,"shortable":3,"etf":0,"ttmEps":-2.982424,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1776196800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":4.01,"postHourTrading":{"tag":"盘后","latestPrice":4.01,"preClose":4.01,"latestTime":"16:10 EDT","volume":6,"amount":24.06,"timestamp":1776111004611,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.830085},"requestUrl":"/m/hq/s/CRVO/wiki","defaultTab":"wiki","newsList":[{"id":"2625553949","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2625553949","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625553949?lang=en_us&edition=fundamental","pubTime":"2026-04-08 20:19","pubTimestamp":1775650740,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 08, 2026 08:19 ET (12:19 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625969377","title":"CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia","url":"https://stock-news.laohu8.com/highlight/detail?id=2625969377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625969377?lang=en_us&edition=fundamental","pubTime":"2026-04-08 04:50","pubTimestamp":1775595044,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) just unveiled an announcement. On April 7, 2026, CervoMed announced that its representatives would present key aspects of the ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-neflamapimod-progress-in-lewy-body-dementia?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-neflamapimod-progress-in-lewy-body-dementia?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4097","PRGS","CRVO","LU2065732104.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625930187","title":"CervoMed says new Phase 2b MRI analysis supports neflamapimod slowing DLB progression","url":"https://stock-news.laohu8.com/highlight/detail?id=2625930187","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625930187?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:06","pubTimestamp":1775563602,"startTime":"0","endTime":"0","summary":"CervoMed outlined updated plans for neflamapimod development in dementia with Lewy bodies at 2026 Lewy Body Dementia Association Annual Meeting.Update included new MRI analyses from Phase 2b RewinD-LB trial that suggest treatment could slow brain changes linked to cognitive decline.Company also highlighted biomarker work indicating blood marker signals tracked with clinical outcomes during neflamapimod treatment.CervoMed said it has completed Phase 3 trial design and reached alignment with global regulators on planned study.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief on April 07, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDL2rfbRD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601708","title":"CervoMed (CRVO) Gets a Buy from JonesTrading","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601708?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:38","pubTimestamp":1775507914,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on CervoMed today and set a price target of $20.00. According to TipRanks, Roy is an analys...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cervomed-crvo-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cervomed-crvo-gets-a-buy-from-jonestrading-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621084075","title":"CervoMed Posts Investor Presentation Under Regulation FD Disclosure","url":"https://stock-news.laohu8.com/highlight/detail?id=2621084075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621084075?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:38","pubTimestamp":1774298305,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has provided an announcement. CervoMed Inc. has posted an investor presentation on its website under the Investors – Events an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-posts-investor-presentation-under-regulation-fd-disclosure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-posts-investor-presentation-under-regulation-fd-disclosure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621008125","title":"Cervomed Inc. Publishes Presentation Factsheet","url":"https://stock-news.laohu8.com/highlight/detail?id=2621008125","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621008125?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:08","pubTimestamp":1774296504,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6qDlWT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620717832","title":"CervoMed Highlights RewinD-LB Phase 2b Biomarker-Driven Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620717832","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620717832?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:59","pubTimestamp":1773953977,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an update. On March 19, 2026, CervoMed reported new analyses from its Phase 2b RewinD-LB trial showing that DLB pat...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-rewind-lb-phase-2b-biomarker-driven-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-highlights-rewind-lb-phase-2b-biomarker-driven-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4233","CRVO","BK4213","BK4139","LB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273125","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273125","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273125?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:42","pubTimestamp":1773945720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 14:42 ET (18:42 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620225398","title":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian,  Biohaven, CervoMed","url":"https://stock-news.laohu8.com/highlight/detail?id=2620225398","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620225398?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:15","pubTimestamp":1773926106,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMedWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: htt","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL6N4070OP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALBmain","EMBC","ACIU","NWMX","KBAB","JBL","CRVO","RIVN","BABU","LIF","RVPH","ALGN","IAUX","XOMZ","NEMG","RIO.AU","89988","SSB","MMM","BABO","FCXG","NEM","HL","SCCO","BHP.AU","HBBD.SI","TRGP","GRDN","HUMA","BHVN","RVNL","APA","CDE","GLSI","DRI","MUD","MULL","ACN","FCX","BBYY","RIO.UK"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620247143","title":"CervoMed’s neflamapimod shows efficacy in dementia with DLB","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247143","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247143?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:56","pubTimestamp":1773921377,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) announced that, at the AD/PD 2026 Conference in Copenhagen, Denmark, investigators will present new analyses from the Phase 2b Rewi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-shows-efficacy-in-dementia-with-dlb-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomeds-neflamapimod-shows-efficacy-in-dementia-with-dlb-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0205193047.USD","LU0205194284.USD","LU0240878834.USD","LU0345774631.USD","LU0240877869.USD","CRVO","BK4139","LU0345774391.USD","BK4097","DLB","LU0348723411.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247581","title":"BRIEF-CervoMed Announces New Data At The Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247581","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247581?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:55","pubTimestamp":1773921319,"startTime":"0","endTime":"0","summary":"BRIEF-CervoMed Announces New Data At The Ad/Pd 2026 Scientific Conference That Reinforce Neflamapimod’S Positive Effects In Dementia With Lewy Bodies (DLB) In Patients Without Alzheimer’S Disease Co-P","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA9BMNHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426662","title":"CervoMed reports Phase 2b neflamapimod benefit in DLB patients with plasma pTau181 below 21 pg/mL","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426662?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:31","pubTimestamp":1773919887,"startTime":"0","endTime":"0","summary":"Investigators will present new analyses from CervoMed’s Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies at the AD/PD 2026 conference.In a within-participant comparison among patients who received placebo then DP Batch B, the CDR-SB difference was -1.11 at screening plasma pTau181 <21 pg/mL .In the extension phase, DP Batch B was associated with expected plasma drug concentration levels, while the initial randomized phase using DP Batch A did not reach expected levels.Across DP batches, 75% of DP Batch B participants versus 50% of DP Batch A participants reached the 4 ng/mL trough threshold .","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL9kX3YD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","IE00BKPKM429.USD","IE00B3QW5Z07.USD","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4139","LU0314104364.USD","SG9999014039.USD","BK4112","SG9999014021.USD","SG9999014013.SGD","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","CRVO","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620572242","title":"CervoMed Announces New Data at the Ad/Pd™ 2026 Scientific Conference That Reinforce Neflamapimod’s Positive Effects in Dementia With Lewy Bodies (Dlb) in Patients Without Alzheimer’s Disease Co-Pathology","url":"https://stock-news.laohu8.com/highlight/detail?id=2620572242","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620572242?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA9BMNHS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620255807","title":"CervoMed Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620255807","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620255807?lang=en_us&edition=fundamental","pubTime":"2026-03-18 20:29","pubTimestamp":1773836940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 08:29 ET (12:29 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620723420","title":"Chardan Raises Price Target on CervoMed to $21 From $15, Keeps Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2620723420","media":"MT Newswires Live","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620723420?lang=en_us&edition=fundamental","pubTime":"2026-03-18 18:24","pubTimestamp":1773829491,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of buy and mean price target of $22.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620401340","title":"CervoMed price target lowered to $11 from $19 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620401340","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620401340?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:00","pubTimestamp":1773788426,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $11 from $19 and keeps a Buy rating on the shares....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-11-from-19-at-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620640957","title":"Chardan Capital Sticks to Their Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620640957","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620640957?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:35","pubTimestamp":1773786922,"startTime":"0","endTime":"0","summary":"In a report released today, Daniil Gataulin from Chardan Capital maintained a Buy rating on CervoMed, with a price target of $21.00. According to T...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620409623","title":"CervoMed price target raised to $21 from $15 at Chardan","url":"https://stock-news.laohu8.com/highlight/detail?id=2620409623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620409623?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:25","pubTimestamp":1773786346,"startTime":"0","endTime":"0","summary":"Chardan raised the firm’s price target on CervoMed (CRVO) to $21 from $15 and keeps a Buy rating on the shares. The neflamapimod program is fully b...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-raised-to-21-from-15-at-chardan-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620180405","title":"CervoMed Reports 2025 Results, Advances Neflamapimod Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2620180405","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620180405?lang=en_us&edition=fundamental","pubTime":"2026-03-18 05:04","pubTimestamp":1773781497,"startTime":"0","endTime":"0","summary":"CervoMed ( ($CRVO) ) has shared an update. On March 17, 2026, CervoMed reported fourth quarter and full-year 2025 results alongside updates on its ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cervomed-reports-2025-results-advances-neflamapimod-programs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","CRVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040351","title":"CervoMed FY2025 net loss rose 66.67% to USD 27 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040351","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040351?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779716,"startTime":"0","endTime":"0","summary":"CervoMed filed a Form 8-K reporting fourth-quarter and full-year 2025 results and corporate updates. Cash, cash equivalents and marketable securities were USD 20.9 million at Dec. 31, 2025, and the company said this is expected to fund operating expenses and capital expenditure for about six months. Full-year grant revenue fell 59% to USD 4 million, reflecting the completion of the randomized phase of the RewinD-LB trial in late 2024 and the extension phase in mid-2025. Full-year R&D expenses rose 16% to USD 21.8 million, driven by higher personnel and consulting costs, CMC work tied to RewinD-LB batch issues and pre-Phase 3 manufacturing improvements, and expenses for the RAS and nfvPPA trials initiated in 2025. Full-year net loss widened to USD 27 million and G&A expenses increased to USD 10.5 million, while CEO John Alam said CervoMed plans to initiate a single global Phase 3 DLB trial in the second half of 2026 subject to funding and expects multiple catalysts in the second half of","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL9TY297:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cervomed.com","stockEarnings":[{"period":"1week","weight":0.0075},{"period":"1month","weight":-0.0565},{"period":"3month","weight":-0.4682},{"period":"6month","weight":-0.5049},{"period":"1year","weight":-0.528},{"period":"ytd","weight":-0.4924}],"compareEarnings":[{"period":"1week","weight":0.0412},{"period":"1month","weight":0.036},{"period":"3month","weight":-0.0111},{"period":"6month","weight":0.0315},{"period":"1year","weight":0.285},{"period":"ytd","weight":0.0061}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.023389},{"month":2,"riseRate":0.5,"avgChangeRate":0.085839},{"month":3,"riseRate":0.5,"avgChangeRate":0.326048},{"month":4,"riseRate":0.4,"avgChangeRate":-0.055866},{"month":5,"riseRate":0.444444,"avgChangeRate":0.146641},{"month":6,"riseRate":0.111111,"avgChangeRate":-0.121539},{"month":7,"riseRate":0.222222,"avgChangeRate":-0.07795},{"month":8,"riseRate":0.666667,"avgChangeRate":0.076308},{"month":9,"riseRate":0.111111,"avgChangeRate":-0.117703},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.039339},{"month":11,"riseRate":0.333333,"avgChangeRate":-0.045938},{"month":12,"riseRate":0.3,"avgChangeRate":-0.206034}],"exchange":"NASDAQ","name":"CervoMed","nameEN":"CervoMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CervoMed,CRVO,CervoMed股票,CervoMed股票老虎,CervoMed股票老虎国际,CervoMed行情,CervoMed股票行情,CervoMed股价,CervoMed股市,CervoMed股票价格,CervoMed股票交易,CervoMed股票购买,CervoMed股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CervoMed(CRVO),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CervoMed(CRVO) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}